These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11828609)

  • 1. Preventing nephropathy in patients with type 2 diabetes.
    Manag Care Interface; 2002 Jan; 15(1):72-5. PubMed ID: 11828609
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
    Jerums G; Cooper ME; Gilbert RE; Atkins RC
    Med J Aust; 2001 Oct; 175(8):397-9. PubMed ID: 11700829
    [No Abstract]   [Full Text] [Related]  

  • 5. [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
    Sidorenko BA; Preobrazhenskiĭ DV; Stetsenko TM; Tarykina EV; Tsurko VV
    Kardiologiia; 2003; 43(2):88-95. PubMed ID: 12891278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kidney and hypertension--evidence based medicine].
    Nakao N; Senou H; Kasuga H; Toriyama T; Kawahara H
    Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1639-45. PubMed ID: 15384696
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Walser M
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract]   [Full Text] [Related]  

  • 10. [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
    Arner P
    Lakartidningen; 2002 Jan; 99(1-2):80-2. PubMed ID: 11871182
    [No Abstract]   [Full Text] [Related]  

  • 11. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
    N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence based treatment of diabetic nephropathy].
    Sugimoto T
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin II receptor blockade in diabetic nephropathy.
    Lewis EJ
    Am J Hypertens; 2003 Jan; 16(1):100-1. PubMed ID: 12517696
    [No Abstract]   [Full Text] [Related]  

  • 15. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 18. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
    Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    Coats AJ
    Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726
    [No Abstract]   [Full Text] [Related]  

  • 20. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.